A groundbreaking experimental vaccine, administered via nasal spray, has shown remarkable promise in mice, offering protection against a wide spectrum of threats including viruses, bacteria, and common allergens. This development could pave the way for a truly "universal" vaccine.
Unlike conventional vaccines that target specific antigens, this new approach stimulates both the adaptive and innate immune systems. The innate system serves as a broad, first-line defense, while the adaptive system provides targeted memory. Researchers observed that mice receiving three doses of the vaccine, known as GLA-3M-052-LS+OVA, were protected for at least three months against SARS-CoV-2, other coronaviruses, Staphylococcus aureus, Acinetobacter baumannii, and house dust mite allergens.
In contrast, unvaccinated mice exhibited significantly worse outcomes, including higher lung inflammation, weight loss, and increased risk of death from infections, and pronounced allergic reactions from allergens. While the results are highly encouraging, the vaccine has only been tested in laboratory animals and requires extensive human trials to confirm its safety and efficacy.